The findings of this study align with prior research that suggests lower effective doses of clozapine are required for patients of Indian descent compared to Western populations. Switching patients of ...
Tardive dyskinesia (TD) can be addressed by the right intervention even in severe, refractory cases. These cases, characterized by involuntary muscle movements, are most often caused by antipsychotics ...
Dipraglurant, a novel oral small molecule negative allosteric modulator of mGlu5 receptor, on track for Phase 2 clinical testing in the second half of 2013 Geneva, Switzerland, 29 January 2013 - Addex ...
Geneva, Switzerland /Chicago, USA, 19 January 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development and the Dystonia Medical ...
Fewer than a hundred cases of paroxysmal dystonia have been described in patients with multiple sclerosis (MS). Even fewer cases of hemidyskinesia triggered by repetitive movements (paroxysmal ...
Accurate and early diagnosis of tardive dyskinesia (TD), a serious movement disorder typically caused by exposure to antipsychotic medications, is imperative for long-term management. "Keeping an eye ...
Currently there are two FDA approved treatment options for tardive dyskinesia. There are two medications that are VMAT2 inhibitors. These are valbenazine (Ingrezza) and deutetrabenazine (Austedo) made ...
Dyskinesia hampers the quality of life for most Parkinson's disease patients following several years of therapy. However, the severity of L-Dopa-induced dyskinesia (LID) varies between patients, being ...
Deep brain stimulation (DBS) may be helpful in severe cases of tardive dyskinesia that doesn’t respond to other treatments. Tardive dyskinesia (TD) causes involuntary movements of the tongue, neck, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback